高管降薪

Search documents
八位董监高集体降薪背后,硕世生物称要“先活下去”
Hua Xia Shi Bao· 2025-08-29 14:09
Core Viewpoint - The company is facing significant operational challenges, leading to a voluntary salary reduction among its senior management as a gesture of solidarity during tough times [2][4][5]. Group 1: Company Performance - In the first half of 2025, the company reported a revenue of 176 million, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million, down 86.35% [2][3]. - The decline in performance is attributed to two main factors: the impact of centralized procurement policies leading to price pressure on products, and an increase in the value-added tax rate for self-produced testing reagents to 13%, which reduced gross margins [3][6]. Group 2: Management Response - Eight senior executives, including the honorary chairman and the chairman, announced voluntary salary reductions ranging from 5% to 50%, effective from August 15, 2025 [2][4]. - The total pre-tax compensation for these executives exceeded 10 million prior to the salary cuts, indicating a significant financial commitment to support the company during its struggles [4][5]. Group 3: Industry Context - The in vitro diagnostic (IVD) industry is experiencing widespread challenges, with many companies facing profit declines or losses due to similar pressures from centralized procurement and fluctuating market demand [6][7]. - The company plans to focus on several strategic areas, including increasing R&D investment, enhancing smart manufacturing, and deepening internationalization, although immediate improvements are uncertain [6][7]. Group 4: Future Outlook - The company remains optimistic about its overseas business potential, although current contributions are small and significant growth is not expected in the short term [6][7]. - Industry experts suggest that technological upgrades and structural adjustments are essential for overcoming current challenges, with a shift towards precision and intelligent diagnostics anticipated in the future [7].
知名药企高管集体降薪,董事长年薪降至百万,此前曾超1600万
2 1 Shi Ji Jing Ji Bao Dao· 2025-08-28 08:52
Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), announced that several executives voluntarily proposed salary reductions in response to ongoing industry challenges and to support long-term development [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua (40% reduction), Hu Yuanyuan (40% reduction), and Zhou Guohui (40% reduction), will also see significant salary cuts, while the financial director and employee supervisors will have reductions of 10% and 5% respectively [2][3]. Executive Compensation Context - Among the seven executives who proposed salary cuts, five had annual salaries exceeding 1 million yuan in 2024, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [3][4]. - The company previously had several executives with annual salaries exceeding 10 million yuan in 2021 and 2022 [4]. Financial Performance - The company has faced continuous operational pressure, with a reported revenue of 176 million yuan in the first half of 2025, a year-on-year decrease of 1.05%, and a net profit of 3.9926 million yuan, down 86.35% [7]. - Shuoshi Biotechnology has recorded net losses for two consecutive years, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively [7]. Dividend Distribution - Despite the decline in performance and executive salary reductions, the company plans to distribute a cash dividend of 2.85 billion yuan for the first half of 2025, reflecting a commitment to return value to shareholders [9]. - The company reported that as of June 30, the undistributed profits exceeded 2.4 billion yuan, allowing for the dividend distribution while maintaining a stable cash flow [9].
知名药企高管集体降薪,董事长年薪降至百万,此前曾超1600万
21世纪经济报道· 2025-08-28 08:38
Core Viewpoint - The company, Shuoshi Biological (688399.SH), announced voluntary salary reductions for several executives, including a 50% cut for the honorary chairman and the chairman/general manager, in response to ongoing financial pressures and to demonstrate solidarity during challenging market conditions [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman/general manager, Wang Guoqiang, will have their salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Tongyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% salary reduction [2][3]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [2][3]. Financial Performance - The company has faced declining financial performance, with a reported revenue of 176 million yuan in the first half of 2025, a decrease of 1.05% year-on-year, and a net profit of 3.99 million yuan, down 86.35% [7]. - The company has experienced net losses for two consecutive years, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively, and corresponding net profits of -374 million yuan and -2 million yuan [7]. Dividend Distribution - Despite the salary cuts and declining performance, the company plans to distribute a cash dividend of 34.00 yuan per 10 shares, totaling 285 million yuan, reflecting a commitment to return value to shareholders [9]. - As of June 30, the parent company had over 2.4 billion yuan in undistributed profits, allowing for this dividend distribution while maintaining a stable cash flow [9].
知名药企高管集体降薪!董事长年薪降至百万,此前曾超1600万
Sou Hu Cai Jing· 2025-08-28 03:57
Core Viewpoint - The company, Shuoshi Biological (688399.SH), announced voluntary salary reductions for several executives, including a 50% cut for the honorary chairman and the chairman/general manager, as a response to ongoing industry challenges and to demonstrate solidarity during tough times [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman/general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Yuanyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% salary reduction [2][3]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [2][3]. Financial Performance - The company reported a revenue of 176 million yuan in the first half of 2025, a decrease of 1.05% year-on-year, with a net profit of 3.99 million yuan, down 86.35% [6]. - Shuoshi Biological has experienced consecutive years of losses, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively, and corresponding net profits of -374 million yuan and -2 million yuan [6]. - Despite the decline in performance, the company plans to distribute a cash dividend of 2.85 billion yuan to shareholders, reflecting a commitment to return value to investors [6]. Company Overview - Shuoshi Biological focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, expanding into in vitro testing services to achieve an integrated business model [6].
A股董事长薪酬出炉:药企霸榜前三,千万级年薪人数越来越少
Sou Hu Cai Jing· 2025-05-08 07:29
Summary of Key Points Core Viewpoint - The report highlights the trends in the annual compensation of chairpersons of A-share listed companies, indicating a decline in the number of chairpersons earning over 10 million yuan, particularly in the context of performance-related pay adjustments across various industries [1][4]. Group 1: Compensation Overview - A total of 4,231 listed companies disclosed their chairpersons' annual compensation, amounting to 5.789 billion yuan [1]. - Thirteen chairpersons earned over 10 million yuan, primarily from the biopharmaceutical, electronics, home appliances, food and beverage, media, and basic chemicals sectors [1]. - The top three earners were from the biopharmaceutical industry: WuXi AppTec's chairperson earned 41.8 million yuan, Mindray Medical's chairperson earned 24.939 million yuan, and BeiGene's chairperson earned 20.194 million yuan [2]. Group 2: Trends in High Compensation - The number of chairpersons with annual salaries exceeding 10 million yuan has decreased from 27 in 2022 to 16 in 2023, and further down to 13 in 2024 [4]. - The distribution of chairpersons' salaries shows a concentration in the 1 million to 2 million yuan range, with 1,402 individuals (one-third of the total) falling within this bracket [3]. Group 3: Salary Adjustments and Performance Impact - Many companies announced salary reductions for executives in 2024, with notable examples including Minglida's chairperson voluntarily waiving half of their salary and Haineng's management team experiencing significant pay cuts [5]. - A total of 3,765 chairpersons had comparable salaries from 2023 to 2024, with 1,377 (37%) experiencing a decrease, while 1,985 (58%) saw an increase [5]. - The primary reason for voluntary salary reductions among high-earning chairpersons was a decline in company performance, as illustrated by the significant pay cuts at Longi Green Energy and Meihua Biological, where chairpersons faced reductions of 92.24% and 83.61%, respectively [6].